Evidence map›Paper›PMID 37732213›Full record

ArticlemedRxiv : the preprint server for health sciences2023

The public health impact of Paxlovid COVID-19 treatment in the United States.

Yuan Bai, Zhanwei Du, Lin Wang, Eric H Y Lau, Isaac Chun-Hai Fung, Petter Holme, Benjamin J Cowling, Alison P Galvani, Robert M Krug, Lauren Ancel Meyers

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 5 countries.

Yuan BaiWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Zhanwei DuWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Lin WangDepartment of Genetics, University of Cambridge, Cambridge, UK.
Eric H Y LauWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Isaac Chun-Hai FungDepartment of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA 30460, USA.
Petter HolmeDepartment of Computer Science, Aalto University, Espoo, FI 00076, Finland.
Benjamin J CowlingWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Alison P GalvaniCenter for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA.
Robert M KrugDepartment of Molecular Biosciences, John Ring LaMontagne Center for Infectious Disease, Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX 78712, USA.
Lauren Ancel MeyersDepartment of Integrative Biology, University of Texas at Austin, Austin, TX 78712, USA.
Hong Kong Science and Technology Parks Corporation · HKGeorgia Southern University · USKobe University · JPSanta Fe Institute · USThe University of Texas at Austin · USUniversity of Cambridge · GBYale University · US

Funding

Accelerating viral outbreak detection in US cities using mechanistic models, machine learning and diverse geospatial dataR01AI151176 · NIAID · YALE UNIVERSITY · PI GALVANI, ALISON P, MEYERS, LAUREN ANCEL · 2020 to 2024
$3.9M
ACL HHS U01IP001136NCIRD CDC HHS U01 IP001136NIAID NIH HHS R01 AI151176
6 · The paper itself

Abstract

The antiviral drug Paxlovid has been shown to rapidly reduce viral load. Coupled with vaccination, timely administration of safe and effective antivirals could provide a path towards managing COVID-19 without restrictive non-pharmaceutical measures. Here, we estimate the population-level impacts of expanding treatment with Paxlovid in the US using a multi-scale mathematical model of SARS-CoV-2 transmission that incorporates the within-host viral load dynamics of the Omicron variant. We find that, under a low transmission scenario

Indexed as

COVID-19mathematical modelPaxlovidpublic health impactSARS-CoV-2 transmissiontreatment

Identifiers

PMID37732213
PMCPMC10508801
OpenAlexW4381190170

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.